文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

达托霉素与重症患者屎肠球菌血流感染治疗失败率较高相关:一项多中心回顾性队列研究

Daptomycin is associated with higher treatment failure rates than alternatives for Enterococcus faecium bloodstream infections in critically ill patients: a multicentric retrospective cohort.
PubMed 文献 · Crit Care · 2025-11-27
一句话结论在ICU屎肠球菌血流感染患者中,以达托霉素作为确定性抗生素方案与较高的治疗失败率相关(aSHR 2.53),需进一步前瞻性研究。

该多中心回顾性队列纳入2017至2022年巴黎大学医院11个ICU的166例成人单微生物屎肠球菌血流感染患者,比较达托霉素(26例,中位剂量10 mg/kg/day)与其他方案(140例,万古霉素69%、利奈唑胺19%、β-内酰胺类11%)作为确定性抗生素方案的疗效。主要复合终点为治疗失败(治疗中菌血症持续≥3天和/或治疗结束后30天内复发和/或30天内需挽救治疗)。多变量Fine and Gray模型显示达托霉素组治疗失败率较高(aSHR 2.53 [1.14-5.62],p=0.022)。作者结论认为达托霉素作为确定性方案与较高治疗失败率相关,需进一步前瞻性研究。

要点

  • 在166例ICU单微生物屎肠球菌血流感染患者中,26例以达托霉素为确定性方案(中位10 mg/kg/day),140例用其他方案(万古霉素69%、利奈唑胺19%、β-内酰胺类11%)。
  • 达托霉素组治疗失败率较高:多变量Fine and Gray模型aSHR 2.53(95%CI 1.14-5.62,p=0.022)。
  • 倾向评分重叠加权敏感性分析结果相似:HR 2.48(95%CI 1.05-5.86,p=0.038)。
  • 仅以万古霉素为对照的敏感性分析:aSHR 2.26(95%CI 1.00-5.10,p=0.051)。
  • 所有分离株均对万古霉素敏感,达托霉素中位MIC为3 mg/L(2-3.25)。

适用人群与场景

  • 2017至2022年巴黎大学医院11个ICU收治的成人单微生物屎肠球菌血流感染患者。

处置流程与药物剂量

  • 达托霉素作为确定性抗生素方案的中位剂量为10 mg/kg/day(原文范围10-10 mg/kg/day)。
  • 非达托霉素方案包括万古霉素(69%)、利奈唑胺(19%)或β-内酰胺类(11%)。

研究设计与关键结果

  • 多中心回顾性队列,纳入166例成人ICU单微生物屎肠球菌血流感染患者;达托霉素组26例,非达托霉素组140例。
  • 主要复合终点(治疗失败)包括:治疗中菌血症持续≥3天、治疗结束后30天内复发、30天内需挽救治疗。
  • 达托霉素组治疗失败率较高:多变量Fine and Gray模型aSHR 2.53(95%CI 1.14-5.62,p=0.022)。
  • 倾向评分重叠加权敏感性分析:HR 2.48(95%CI 1.05-5.86,p=0.038)。
  • 仅以万古霉素为对照的敏感性分析:aSHR 2.26(95%CI 1.00-5.10,p=0.051)。
  • 达托霉素组与非达托霉素组达到适当抗生素方案的时间(1 [0-2] vs 1 [0-2]天,p=0.22)和感染源控制率(63% vs 43%,p=0.17)无显著差异。
  • 血流感染来源主要为未知(38%)、消化道(37%)或血管内装置(16%)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文报告需进一步前瞻性研究。

对床旁实践的改变

  • 作者认为,在ICU单微生物屎肠球菌血流感染患者中,以达托霉素作为确定性抗生素方案与较高的治疗失败率相关;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Enterococcal infections represent 10% of intensive care unit (ICU)-acquired infections and are associated with adverse outcomes, particularly in the case of E. faecium infections. Some studies focusing on non-critically ill patients have cast doubt on the non-inferiority of daptomycin compared to other antibiotics for these infections. We aimed to describe antibiotic treatment practices for monomicrobial E. faecium bloodstream infections (BSI) in patients admitted to the ICU, and to identify factors associated with treatment failure.

METHODS: This retrospective multicenter study included adult patients presenting with a monomicrobial E. faecium BSI during their stay in one of 11 ICUs of Paris University hospitals between 2017 and 2022. Patients receiving daptomycin as a definitive antibiotic regimen were compared to those receiving another molecule using competing-risks models and propensity score-based analyses. The primary outcome was a composite criterion of treatment failure including: (1) prolonged bacteremia (≥3days) under treatment and/or (2) relapse within 30 days after the end of treatment and/or (3) the need for salvage therapy within 30 days.

RESULTS: Of the 166 included patients, 26 received daptomycin as a definitive antibiotic regimen, at a median dose of 10 [10-10] mg/kg/day and 140 patients received non-daptomycin-based regimens (vancomycin (69%), linezolid (19%) or a beta-lactam (11%)). Source of BSI was predominantly unknown (38%), digestive (37%) or an intravascular device (16%). All isolates were vancomycin-susceptible. Median daptomycin MIC was 3 [2-3.25] mg/L. Time to adequate antibiotic regimen (1 [0-2] vs 1 [0-2] days, p=0.22) and rates of source control (63% vs 43%, p=0.17) were not different between groups. Regarding primary outcome, daptomycin as a definitive antibiotic regimen was associated with a higher rate of treatment failure in the multivariate adjusted analysis using a Fine and Gray model (aSHR 2.53 [1.14-5.62], p=0.022). Sensitivity analyses using propensity score overlap weighting (HR 2.48 [1.05-5.86], p=0.038) or with only patients treated by vancomycin as comparators (aSHR 2.26 [1.00-5.10], p=0.051) yielded similar results.

CONCLUSIONS: In this multicenter retrospective cohort of critically ill patients with monomicrobial E. faecium bloodstream infections, use of daptomycin as the definitive antibiotic regimen was associated with a higher rate of treatment failure. Further prospective studies are needed.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Herbel S, Dumas G, Chantelot L, et al. Daptomycin is associated with higher treatment failure rates than alternatives for Enterococcus faecium bloodstream infections in critically ill patients: a multicentric retrospective cohort. Crit Care. 2025. PMID: 41310831. doi:10.1186/s13054-025-05733-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。